Skip to content
value.today

BioDrain Medical, Inc.

Total raised
$2 M
1 round on record
Latest round
$2 M
Jun 2008
First round on record
Jun 2008
Today
Went public
See the company page

BioDrain Medical, Inc. is listed today as Axe Compute Inc.: market value, financials and filings are on its company page.

Funding rounds

1 counted as startup funding, 12 other private sales on record. Open the number of investors for the round's details.

Funding rounds of BioDrain Medical, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Oct 2025$51 MPrivate placement after listing$50 to $250 million

BioDrain Medical, Inc.: Private sale, Oct 2025

Investors in this round

29 investors had bought by the notice of Oct 22, 2025: 29 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$51 M of $51 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$2,538,481
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Josh S. Blacher · Executive Officer
  • Raymond F. Vennare · Executive Officer, Director
  • Thomas L. McLaughlin · Executive Officer
  • Chuck S. Nuzum · Director
  • Dan S. Hadley · Director
  • Gregory S. St. Clair, Sr. · Director
  • Matthew S. Hawryluk · Director
  • Shawn S. Matthews · Director
  • Veena F. Rao · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • H. C. Wainwright & Co., LLC (CRD 375) · New York, New YorkSold in CA, CO, CT, FL, HI, IL, MA, MN, NJ, NV, NY, PA, PR, TN, TX, WA, and outside the US

Remarks in the notice

  • On fees: “In addition to the cash fee reflected above, H.C. Wainwright & Co., LLC or its designees were issued warrants to purchase an aggregate of 218,335 shares of the Issuer's common stock.”

Signed by Raymond Vennare, Chief Executive Officer. Newest notice filed Oct 22, 2025 (1 amendment). Read the notice at the SEC.

equity, optionsSEC
Jul 2024$2 MPrivate placement after listing$2 to $10 million

BioDrain Medical, Inc.: Private sale, Jul 2024

Investors in this round

8 investors had bought by the notice of Aug 2, 2024: 8 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$2 M of $2 M offered
Smallest investment taken
no minimum stated
What was sold
options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
$1 million to $5 million
Sales commissions
$262,789
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Josh Blacher · Executive Officer · The above amount includes a 1% management fee. The Placement agent also received warrants to purchase an aggregate 67,06
  • Raymond Vennare · Executive Officer, Director
  • Chuck S. Nuzum · Director
  • Dan S. Hadley · Director
  • Gregory S. St. Clair, Sr. · Director
  • Matthew S. Hawryluk · Director
  • Nancy S. Chung-Welch · Director
  • Veena S. Rao · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • H.C. Wainwright & Co., LLC (CRD 375) · broker-dealer H.C. Wainwright & Co., LLC (CRD 375) · New York, New YorkSold in FL, IL, NY, and outside the US

Remarks in the notice

  • On fees: “The above amount includes a 1% management fee. The Placement agent also received warrants to purchase an aggregate 67,068 shares of Common Stock.”

Signed by Raymond Vennare, Ceo. Newest notice filed Aug 2, 2024. Read the notice at the SEC.

optionsSEC
May 2022$2 MPrivate placement after listing$2 to $10 million

BioDrain Medical, Inc.: Private sale, May 2022

Investors in this round

4 investors had bought by the notice of Jun 2, 2022: 4 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$2 M of $2 M offered
Smallest investment taken
no minimum stated
What was sold
options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
$1 million to $5 million
Sales commissions
$195,702
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks sales commissions and payments to its own people as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Bob Melville Myers · Executive Officer
  • J Melville Engle · Executive Officer, Director
  • Christina E Jenkins · Director
  • Chuck Melville Nuzum · Director
  • Daniel E Handley · Director
  • Gregory E St. Clair · Director
  • Nancy E Chung-Welch · Director
  • Raymond E Vennare · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • H.C. Wainwright & Co. LLC (CRD 375) · broker-dealer H.C. Wainwright & Co. LLC (CRD 375) · New York, New YorkSold in IL, NJ, NV, NY

Remarks in the notice

  • On fees: “The above amount includes a 1% management fee. The Placement Agent also received Warrants to purchase an aggregate of 900,000 shares of Common Stock.”
  • On the amounts: “Above amount includes proceeds from the sale of common stock pursuant to a concurrent registered direct offering, as well as the common stock purchase warrants covered by this filing and does not include proceeds from the exercise of such warrants.”

Signed by Bob Myers, Chief Financial Officer. Newest notice filed Jun 2, 2022 (1 amendment). Read the notice at the SEC.

optionsSEC
Feb 2021$18 MPrivate placement after listing$10 to $50 million

BioDrain Medical, Inc.: Private sale, Feb 2021

Investors in this round

19 investors had bought by the notice of Mar 18, 2021: 19 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$18 M of $18 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$1,579,954
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks sales commissions and payments to its own people as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Bob I Myers · Executive Officer
  • Carl I Schwartz · Executive Officer, Director
  • Chuck S Nuzum · Director
  • Daniel E Handley · Director
  • Gregory S St. Clair Sr. · Director
  • J Melville Engle · Director
  • Nancy S Chung-Welch · Director
  • Richard L Gabriel · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • H.C. Wainwright & Co. LLC (CRD 375) · broker-dealer H.C. Wainwright & Co. LLC (CRD 375) · New York, New YorkSold in CA, FL, IL, NJ, NY

Remarks in the notice

  • On fees: “The above amount includes a 1% management fee. The Placement Agent also received Warrants to purchase an aggregate of 678,282 shares of Common Stock.”

Signed by Bob Myers, Chief Financial Officer. Newest notice filed Mar 18, 2021. Read the notice at the SEC.

equity, optionsSEC
Jan 2021$17 MPrivate placement after listing$10 to $50 million

BioDrain Medical, Inc.: Private sale, Jan 2021

Investors in this round

10 investors had bought by the notice of Mar 18, 2021: 10 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$17 M of $17 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$950,958
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks sales commissions and payments to its own people as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Bob I Myers · Executive Officer
  • Carl I Schwartz · Executive Officer, Director
  • Chuck S Nuzum · Director
  • Daniel E Handley · Director
  • Gregory S St. Clair Sr. · Director
  • J Melville Engle · Director
  • Nancy S Chung-Welch · Director
  • Richard L Gabriel · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • H.C. Wainwright & Co. LLC (CRD 375) · broker-dealer H.C. Wainwright & Co. LLC (CRD 375) · New York, New YorkSold in CA, FL, IL, NJ, NY

Remarks in the notice

  • On fees: “The above amount includes a 1% management fee. The Placement Agent also received Warrants to purchase an aggregate of 1,328,350 shares of Common Stock.”

Signed by Bob Myers, Chief Financial Officer. Newest notice filed Mar 18, 2021 (1 amendment). Read the notice at the SEC.

equity, optionsSEC
Jul 2020$2 MPrivate placement after listingUnder $2 million

BioDrain Medical, Inc.: Private sale, Jul 2020

Investors in this round

18 investors had bought by the notice of Jul 10, 2020: 18 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$2 M of $2 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Bob I Myers · Executive Officer
  • Carl I Schwartz · Executive Officer, Director, Promoter
  • Andrew P Reding · Director
  • Daniel E Handley · Director
  • J Melville Engle · Director
  • Richard L Gabriel · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On a merger: “Quantitative Medicine LLC”

Signed by Bob Myers, Chief Financial Officer. Newest notice filed Jul 10, 2020. Read the notice at the SEC.

equitySEC
Mar 2020$4 MPrivate placement after listing$2 to $10 million

BioDrain Medical, Inc.: Private sale, Mar 2020

Investors in this round

2 investors had bought by the notice of Mar 30, 2020: 2 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$4 M of $4 M offered
Smallest investment taken
$1,500,000
What was sold
equity, options or other rights to buy securities
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$262,500
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks sales commissions and payments to its own people as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Bob E Myers · Executive Officer
  • Carl Schwartz · Executive Officer, Director
  • Andrew E Reding · Director
  • Daniel E Handley · Director
  • Gerald J Vardzel · Director
  • J Melville Engle · Director
  • Pam S Prior · Director
  • Richard L Gabriel · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • H.C. Wainwright & Co. (CRD 375) · broker-dealer H.C. Wainwright &Co. (CRD 375) · New York, New YorkSold in NJ, NY

Remarks in the notice

  • On fees: “Plus management fee of $35,000 and non-accountable expense fees of $25,000 and warrant to purchase 84,777 shares”

Signed by Bob Myers, Chief Financial Officer and Secretary. Newest notice filed Mar 30, 2020. Read the notice at the SEC.

equity, optionsSEC
Jun 2019$1 MPrivate placement after listingUnder $2 million

BioDrain Medical, Inc.: Private sale, Jun 2019

Investors in this round

11 investors had bought by the notice of Jul 29, 2019: 11 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$1 M of $4 M offered; $2 M still to sell
Smallest investment taken
$50,000
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$121,120
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks sales commissions and payments to its own people as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Bob A Myers · Executive Officer
  • Carl Schwartz · Executive Officer, Director
  • Andrew A Reding · Director
  • Gerald J Vardzel · Director
  • J Melville Engle · Director
  • Richard L Gabriel · Director
  • Thomas A McGoldrick · Director
  • Timothy A Krochuk · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • David Weinstein (CRD 130645) · broker-dealer Dawson James Securities, Inc. (CRD 130645) · Boca Raton, FloridaSold in AZ, CT, IL, MD, MN, VA, WA

Remarks in the notice

  • On fees: “Includes expense allowance”
  • On the amounts: “Series E Convertible Preferred”

Signed by Bob Myers, Chief Financial Officer and Secretary. Newest notice filed Jul 29, 2019. Read the notice at the SEC.

equitySEC
Sep 2018$2 MPrivate placement after listing$2 to $10 million

BioDrain Medical, Inc.: Private sale, Sep 2018

Investors in this round

2 investors had bought by the notice of Oct 11, 2018: 2 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$2 M of $3 M offered; $1 M still to sell
Smallest investment taken
$600,000
What was sold
debt, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$160,000
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks sales commissions as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Bob A Myers · Executive Officer
  • Carl Schwartz · Executive Officer, Director
  • Andrew A Reding · Director
  • J Melville Engle · Director
  • Richard L Gabriel · Director
  • Thomas A McGoldrick · Director
  • Timothy A Krochuk · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • David Weinstein (CRD 130645) · broker-dealer Dawson James Securities, Inc. (CRD 130645) · Boca Raton, FloridaSold in FL, PR

Remarks in the notice

  • On fees: “Includes expense allowance”

Signed by Bob Myers, Chief Financial Officer and Secretary. Newest notice filed Oct 11, 2018. Read the notice at the SEC.

debt, optionsSEC
Nov 2017$1 MPrivate placement after listingUnder $2 million

BioDrain Medical, Inc.: Private sale, Nov 2017

Investors in this round

1 investor had bought by the notice of Dec 12, 2017: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$1 M of $1 M offered
Smallest investment taken
$1,300,000
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$104,000
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks sales commissions as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Bob A Myers · Executive Officer
  • Carl Schwartz · Executive Officer, Director
  • David Johnson · Executive Officer
  • Andrew A Reding · Director
  • J Melville Engle · Director
  • Richard L Gabriel · Director
  • Thomas A McGoldrick · Director
  • Timothy A Krochuk · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • David Weinstein (CRD 130645) · broker-dealer Dawson James Securities, Inc. (CRD 130645) · Boca Raton, FloridaSold in NY

Remarks in the notice

  • On fees: “In addition to sales commissions, the broker/dealer received a warrant equal to 5% of the amount of the underlying common stock sold in the offering and a legal expense allowance of $5,000.”

Signed by Bob Myers, Chief Financial Officer and Secretary. Newest notice filed Dec 12, 2017. Read the notice at the SEC.

equity, optionsSEC
Jan 2014$2 MPrivate placement after listing$2 to $10 million

BioDrain Medical, Inc.: Private sale, Jan 2014

Investors in this round

16 investors had bought by the notice of Feb 5, 2014: 16 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$2 M of $2 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
$50,000 (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks payments to its own people as estimates
The company
Corporation, incorporated in Minnesota

People named in the notice

  • Bob Myers · Executive Officer
  • David Johnson · Executive Officer
  • Joshua Kornberg · Executive Officer, Director
  • Andrew Reding · Director
  • Arnon Dreyfuss · Director
  • Frank Mancuso · Director
  • Ricardo Koenigsberger · Director
  • Thomas McGoldrick · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the use of proceeds: “Salaries”

Signed by Bob Myers, Chief Financial Officer and Secretary. Newest notice filed Feb 5, 2014. Read the notice at the SEC.

equity, optionsSEC
May 2013$1 MPrivate placement after listingUnder $2 million

BioDrain Medical, Inc.: Private sale, May 2013

Investors in this round

13 investors had bought by the notice of Jun 20, 2013: 13 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$1 M of $1 M offered
Smallest investment taken
$25,000
What was sold
debt, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 505: the former limited-offering exemption (withdrawn in 2017)
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$80,000
Finders' fees
none
Paid to its own people
$50,000 (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks payments to its own people as estimates
The company
Corporation, incorporated in Minnesota

People named in the notice

  • Bob P. Myers · Executive Officer
  • David P. Johnson · Executive Officer
  • Joshua W. Kornberg · Executive Officer, Director
  • Lawrence W. Gadbaw · Executive Officer, Director
  • Andrew P. Reding · Director
  • Peter L. Morawetz · Director
  • Ricardo P. Koenigsberger · Director
  • Thomas J. McGoldrick · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Brookline Group, LLC (CRD 153587) · broker-dealer Brookline Group, LLC (CRD 153587) · Birmingham, AlabamaSold in AL, AR, AZ, CA, CO, CT, DC, DE, FL, GA, ID, IL, IN, KS, LA, MA, MD, MI, MN, MO, MS, NC, NE, NJ, NV, NY, OH, OK, OR, PA, RI, SC, TN, TX, UT, VA, WA, WI, WV, WY

Remarks in the notice

  • On the use of proceeds: “Salaries”

Signed by Bob Myers, Chief Financial Officer. Newest notice filed Jun 20, 2013. Read the notice at the SEC.

debt, optionsSEC
Jun 2008$2 MNo. 1Under $2 million

BioDrain Medical, Inc.: Raise no. 1, Jun 2008

Investors in this round

32 investors had bought by the notice of Nov 4, 2009: 32 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$2 M of $2 M offered; $1 M still to sell
Smallest investment taken
$3,000
What was sold
equity
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
No revenue
Sales commissions
none
Finders' fees
none
Paid to its own people
$268,500 (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Minnesota

People named in the notice

  • Alan P. Shuler · Executive Officer · Mr. Shuler serves as the Corporate Secretary.
  • Chad A. Ruwe · Executive Officer, Director · Mr. Ruwe serves as the Chief Operating Officer and Director.
  • Kevin R. Davidson · Executive Officer, Director · Mr. Davidson serves as the President, Chief Executive Officer, Chief Financial Officer and Director.
  • Kirsten A. Doerfert · Executive Officer · Ms. Doerfert serves as the Vice President of Sales and Marketing.
  • Andrew P. Reding · Director
  • James E. Dauwalter · Director
  • Lawrence W. Gadbaw · Director · Mr. Gadbaw serves as the Chairman of the Board of Directors.
  • Peter L. Morawetz · Director
  • Thomas J. McGoldrick · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the use of proceeds: “Executive officer salaries and board chairman fees.”

Signed by Kevin R. Davidson, President, Chief Executive Officer & Chief Financial Officer. Newest notice filed Nov 4, 2009. Read the notice at the SEC.

equitySEC

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • As the listed company Axe Compute Inc., its revenue in fiscal 2024 came from these business segments: Drug Discovery Services $80,000 (100%).

    Annual report (SEC XBRL) · Dec 2024

  • BioDrain Medical, Inc. chose not to state its revenue in its newest notice of a funding round (Oct 2025).

    SEC Form D · Oct 2025

  • Revenue range over time, as stated in its notices: no revenue in 2009; revenue between $1 million and $5 million in 2022; revenue between $1 million and $5 million in 2024.

    SEC Form D (revenue range) · Aug 2024

  • The industry group it chose in its notices: Other Health Care.

    SEC Form D · Oct 2025

Products and services#

No products or services of BioDrain Medical, Inc. are on record.

Investors#

No investor of BioDrain Medical, Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Largest shareholders today

Institutions holding Axe Compute Inc. shares, as of Sep 30, 2026.

As of Sep 30, 2026

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by BioDrain Medical, Inc.
NameRoleNamed in
Josh S. BlacherExecutive officerOct 2025
Raymond F. VennareExecutive officerOct 2025
Thomas L. McLaughlinExecutive officerOct 2025
Josh BlacherThe above amount includes a 1% management fee. The Placement agent also received warrants to purchase an aggregate 67,06Aug 2024
Raymond VennareExecutive officerAug 2024
Bob Melville MyersExecutive officerJun 2022
J Melville EngleExecutive officerJun 2022
Bob I MyersExecutive officerMar 2021
Carl I SchwartzExecutive officerMar 2021
Bob E MyersExecutive officerMar 2020
Carl SchwartzExecutive officerMar 2020
Bob A MyersExecutive officerJul 2019
David JohnsonExecutive officerDec 2017
Bob MyersExecutive officerFeb 2014
Joshua KornbergExecutive officerFeb 2014
Bob P. MyersExecutive officerJun 2013
David P. JohnsonExecutive officerJun 2013
Joshua W. KornbergExecutive officerJun 2013
Lawrence W. GadbawExecutive officerJun 2013
Alan P. ShulerMr. Shuler serves as the Corporate Secretary.Nov 2009
Chad A. RuweMr. Ruwe serves as the Chief Operating Officer and Director.Nov 2009
Kevin R. DavidsonMr. Davidson serves as the President, Chief Executive Officer, Chief Financial Officer and Director.Nov 2009
Kirsten A. DoerfertMs. Doerfert serves as the Vice President of Sales and Marketing.Nov 2009
Chuck S. NuzumDirectorOct 2025
Dan S. HadleyDirectorOct 2025
Gregory S. St. Clair, Sr.DirectorOct 2025
Matthew S. HawrylukDirectorOct 2025
Raymond F. VennareDirectorOct 2025
Shawn S. MatthewsDirectorOct 2025
Veena F. RaoDirectorOct 2025
Nancy S. Chung-WelchDirectorAug 2024
Raymond VennareDirectorAug 2024
Veena S. RaoDirectorAug 2024
Christina E JenkinsDirectorJun 2022
Chuck Melville NuzumDirectorJun 2022
Daniel E HandleyDirectorJun 2022
Gregory E St. ClairDirectorJun 2022
J Melville EngleDirectorJun 2022
Nancy E Chung-WelchDirectorJun 2022
Raymond E VennareDirectorJun 2022

Went public since 2012. Its SEC number is that of a company listed on a stock exchange.